Stem Cell Therapy for Parkinson's: New Data at ISSCR 2026
Researchers presented 12-month clinical data from the STEM-PD trial at the ISSCR 2026 meeting, showing the safety and feasibility of stem cell-derived dopaminergic cell transplantation for Parkinson's disease. This study marks a significant advancement in regenerative medicine by moving beyond proof-of-concept toward clinical application.
Why it matters
This represents a potential breakthrough in treating neurodegenerative diseases by replacing lost neurons rather than just managing symptoms.
The International Society for Stem Cell Research (ISSCR) today announced the presentation of new clinical data from the STEM-PD Phase I/II clinical trial at the ISSCR 2026 Annual Meeting. The study reports 12-month outcomes evaluating a cryopreserved, off-the-shelf dopaminergic progenitor cell product derived from human pluripotent stem cells for the treatment of Parkinson's disease.
The article summarizes scientific findings and expert commentary without bias.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in